SecProbe.io

CORRESP
1
filename1.htm

              Harry
      S. Palmin

              President
      and CEO

              hpalmin@novelos.com

    VIA
EDGAR

    Securities
and Exchange Commission

    Division
of Corporation Finance

    450 Fifth
Street, N.W.

    Washington,
D.C.  20549

    July 7,
2010

              Re:

              Novelos
      Therapeutics, Inc.

              Registration Statement
      on Form S-1 (File No.
333-166744)

    Ladies
and Gentlemen:

    On July
7, 2010, Novelos Therapeutics, Inc., a Delaware corporation (the “Company”),
filed Amendment No. 2 to Registration Statement on Form S-1, File No. 333-166744
(the “Registration Statement”).

    Pursuant
to Rule 461(a) under the Securities Act of 1933, as amended, the Company hereby
requests that the effectiveness of the Registration Statement be accelerated so
that the Registration Statement will become effective at 4:30 p.m., Eastern
time, on Thursday, July 8, 2010, or as soon as practicable
thereafter.

    The
Company acknowledges that:

              ·

              should
      the Commission or the staff, acting pursuant to delegated authority,
      declare the filing effective, it does not foreclose the Commission from
      taking any action with respect to the
filing;

              ·

              the
      action of the Commission or the staff, acting pursuant to delegated
      authority, in declaring the filing effective, does not relieve the Company
      from its full responsibility for the adequacy and accuracy of the
      disclosure in the filing; and

              ·

              the
      Company may not assert staff comments and the declaration of effectiveness
      as a defense in any proceeding initiated by the Commission or any person
      under the federal securities laws of the United
  States.

      Novelos Therapeutics,
Inc.  One Gateway Center, Suite 504  Newton, MA
02458  617.244.1616  Fax 964.6331

    Please
advise Paul Bork of Foley Hoag LLP at 617-832-1113 or, in his absence, Matthew
Eckert at 617-832-3057, when the Registration Statement has been declared
effective or if the Staff has any questions.

    Thank you
for your cooperation.

              Very
      truly yours,

              Novelos
      Therapeutics, Inc.

                By:

              /s/ Harry
      S. Palmin

              Harry
      S. Palmin, President and CEO

              cc:

              Mr.
      Jeffrey Riedler

              Paul Bork,
Esq.

        - 2
-